CT Vascular Pruning Markers Identify Chronic Vasculopathy in Sickle Cell Disease

Quantifying Pulmonary Vasculopathy in Sickle Cell Disease

Sickle cell disease involves systemic vasculopathy and chronic organ damage, necessitating the development of robust biomarkers to track disease progression and treatment response [1]. Pulmonary complications remain a primary driver of mortality, often manifesting as impaired gas exchange, chronic parenchymal changes, or secondary pulmonary hypertension [2]. While traditional metrics like carbon monoxide diffusing capacity provide essential functional data, they do not always capture the specific structural remodeling occurring within the pulmonary vascular bed [2]. The search for non-invasive imaging markers to differentiate vascular phenotypes and identify early remodeling is a priority in chronic diseases characterized by microvascular rarefaction (the progressive loss or thinning of the smallest blood vessels) [3]. Accurate assessment of these vascular changes is critical for identifying patients at risk for long-term complications such as pulmonary embolism or right heart failure [4]. A recent study investigates whether automated quantification of small-vessel rarefaction on routine imaging can bridge this diagnostic gap.

Automated Metrics for Small Vessel Rarefaction

The study evaluated 73 adult patients with sickle cell disease (mean age 33 ± 14 years; 38 women, representing 52.1% of the cohort) who were followed at Avicenne Hospital in Paris, France. Researchers utilized routine non-contrast chest CT scans to perform a quantitative assessment of pulmonary vascular pruning, a clinical term describing the rarefaction or loss of small-caliber pulmonary vessels. This automated quantitative analysis of pulmonary vessels on non-contrast chest CT can reveal vascular pruning and provide imaging biomarkers of pulmonary vasculopathy, offering a non-invasive tool to understand the complex pulmonary complications associated with sickle cell disease. By utilizing standard imaging rather than specialized contrast-enhanced protocols, this approach integrates more easily into the existing clinical workflow for monitoring chronic patients.

To quantify these vascular changes, the researchers employed specific imaging metrics focused on small-vessel distribution. The primary biomarker used was the blood volume in vessels with a cross-sectional area less than 5 mm² (BV5), which serves as a proxy for the health of the distal microvasculature. Additionally, the researchers calculated the ratio of BV5 to total pulmonary blood volume (TBV) to assess the relative proportion of small vessels within the entire pulmonary circulatory bed. These pulmonary vascular volumes were measured both globally across the entire lung and specifically within peripheral lung regions to capture localized rarefaction. By establishing these metrics, the study demonstrates that automated metrics can identify structural changes in the microvasculature that may correlate with chronic vascular damage, providing a more objective measure than qualitative visual assessment.

Correlation with Parenchymal and Proximal Vascular Damage

The researchers identified a high prevalence of structural lung changes within the cohort of 73 patients, highlighting the extent of chronic tissue damage. Linear opacities (focal, line-like areas of increased density on CT) were present in 78% of patients, while reticulations (a pattern of fine lines suggesting interstitial thickening) were observed in 53.4% of patients. These parenchymal abnormalities often reflect the cumulative impact of chronic lung injury, such as repeated episodes of acute chest syndrome or chronic infarction, in sickle cell disease. The study demonstrated that the presence of these structural changes was not merely incidental but was significantly associated with reduced BV5 and BV5/TBV, the quantitative markers used to measure small vessel volume.

Beyond the lung tissue itself, the study examined the larger vessels of the pulmonary circulatory system for signs of remodeling. Pulmonary trunk enlargement was observed in 28.8% of patients, and segmental artery dilation was found in 19.2% of patients. These proximal vascular abnormalities, which often serve as clinical indicators of elevated pulmonary pressures, also showed a significant association with reduced BV5 and BV5/TBV. Because reduced BV5 and BV5/TBV indicate increased vascular pruning (the loss or rarefaction of small-caliber vessels), these findings suggest that the disappearance of the microvasculature is closely linked to the compensatory or pathological remodeling of larger pulmonary arteries. This link is clinically vital, as it suggests that distal vessel loss may precede or drive the proximal arterial changes often seen in advanced pulmonary hypertension.

The integration of these findings establishes that pulmonary vascular pruning is observed in sickle cell disease in association with both parenchymal and vascular abnormalities. For the practicing physician, this means that the automated quantification of small vessels provides a metric that mirrors visible structural damage. The significant correlation between reduced small vessel volume and findings such as linear opacities, reticulations, and arterial dilation suggests that vascular pruning may serve as a comprehensive indicator of chronic vasculopathy. This quantitative approach allows for a more precise assessment of the total burden of pulmonary disease than visual inspection alone, potentially identifying patients with significant underlying vascular rarefaction before it manifests as overt clinical failure.

Clinical Significance and Functional Impairment

Sickle cell disease causes pulmonary parenchymal and vascular complications that exert a major impact on patient mortality. To determine if automated CT metrics reflect these clinical realities, the researchers compared the vascular biomarkers against pulmonary function tests, CT parenchymal abnormalities, and the clinical history of vascular disease in the 73 patients. The analysis revealed that vascular pruning markers were significantly associated with a hemoglobin-corrected diffusing capacity for carbon monoxide (DLCOc) of less than 80%, a measurement that quantifies the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. This correlation suggests that the rarefaction of small vessels captured by BV5 and BV5/TBV metrics directly corresponds to impaired gas exchange, providing a structural explanation for functional respiratory deficits observed in the clinic.

The clinical utility of these markers is further supported by their strong correlation with high-risk cardiovascular events. The study found that pruning markers were significantly associated with a history of pulmonary embolism and pulmonary hypertension, both of which are severe complications of the chronic vasculopathy inherent to sickle cell disease. While the primary findings relied on global lung measurements, a peripheral lung analysis showed trends consistent with global measurements, with some differences in statistical significance, suggesting that vascular loss occurs throughout the lung but may be most reliably quantified when considering the entire pulmonary volume. These associations underscore the potential for automated CT analysis to identify patients who have already sustained significant vascular remodeling, which may assist in risk stratification for right-sided heart failure.

Notably, the researchers observed that no significant relationship was found between vascular pruning and acute vaso-occlusive episodes, the painful crises that often lead to emergency department visits. This lack of association is clinically instructive, as it suggests that the loss of small pulmonary vessels is a marker of chronic, progressive pathology rather than a transient state related to acute sickling events. Because these CT-derived markers identify chronic vasculopathy and correlate with established risks like pulmonary hypertension, they may serve as early imaging biomarkers to identify patients at the highest risk for long-term complications and mortality. For the practicing clinician, this quantitative approach offers a non-invasive method to detect silent vascular rarefaction during routine chest imaging, potentially allowing for earlier intervention before the onset of irreversible respiratory failure.

References

1. Farrell AT, Panepinto JA, Carroll CP, et al. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances. 2019. doi:10.1182/bloodadvances.2019000882

2. Hayes, Black, Jenkinson, et al. Outcome measures for adult critical care: a systematic review.. Health Technology Assessment. 2000. doi:10.3310/hta4240

3. Wang N, Sourbron S, Benemerito I, Marzo A. A Virtual Trial to Identify Cardiovascular Biomarkers for Differentiating Diabetic and Hypertensive Kidney Disease. Annals of Biomedical Engineering. 2026. doi:10.1007/s10439-026-03983-4

4. Members AF, Konstantinides S, Torbicki A, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2014. doi:10.1093/eurheartj/ehu283